Interferon alpha might be an alternative therapeutic choice for refractory Neuro-Behçet's disease
- 1 April 2019
- journal article
- letter
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 29, 153
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Which treatment strategies for polyrefractory Neuro-Behçet disease?Multiple Sclerosis and Related Disorders, 2019
- 2018 update of the EULAR recommendations for the management of Behçet's syndromeAnnals of the Rheumatic Diseases, 2018
- Interferon- treatment for acute myelitis and intestinal involvement in severe Behcet's diseaseQJM: An International Journal of Medicine, 2010
- Biologics in the treatment of uveitisCurrent Opinion in Ophthalmology, 2007
- Transverse myelitis in a patient with Behcet’s disease: favorable outcome with a combination of interferon-αClinical Rheumatology, 2004
- Effects of interferon α treatment on the clinical course of refractory Behçet's disease: an open studyAnnals of the Rheumatic Diseases, 2003
- Interferon-Alpha 2a Treatment of Neuro-Behcet DiseaseJournal of Neuro-Ophthalmology, 2001
- Beh et's syndrome: Treatment with recombinant leukocyte alpha-interferonArchives of Dermatological Research, 1986